Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EuroNet-PHL-C2 first-line treatment strategy for pediatric and adolescent classical Hodgkin lymphoma
ACTRN12618000069257Phase 3Completed
- Sponsor
- Justus Liebig University Giessen
- Start
- Mar 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of prednisone, prednisolone, vincristine, doxorubicin, etoposide and 3 more in classical Hodgkin lymphoma (cHL) (3 arms), sponsored by Justus Liebig University Giessen. Primary endpoint: Event-free survival. Started Mar 2015; status: completed.
02
Drugs
prednisoneprednisolonevincristinedoxorubicinetoposide
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on ACTRN12618000069257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000069257.